Marco Proietti1, Cécile Laroche2, Marcin Drozd3, Johan Vijgen4, Dragos C Cozma5, Jaroslaw Drozdz6, Aldo P Maggioni7, Giuseppe Boriani8, Gregory Y H Lip9. 1. University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom. 2. EURObservational Research Programme Department, European Society of Cardiology, Sophia Antipolis, France. 3. Department of Cardiology, Center for Heart Diseases, Military Hospital, Wroclaw, Poland; Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. 4. Department of Cardiology, Jessa Hospitlas, Hasselt, Belgium. 5. Institute of Cardiovascular Medicine, Timisoara, Victor Babes University of Medicine and Pharmacy of Timisoara, Timisoara, Romania. 6. Medical University, Lodz, Poland. 7. EURObservational Research Programme Department, European Society of Cardiology, Sophia Antipolis, France; ANMCO Research Center, Firenze, Italy. 8. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, S. Orsola-Malpighi University Hospital, Bologna, Italy; Cardiology Department, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy. 9. University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: g.y.h.lip@bham.ac.uk.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a common chronic disease, being associated with both high rates of morbidity and mortality. Similarly, atrial fibrillation (AF) is associated with a higher risk of both cardiovascular (CV) events and overall mortality. The AF and COPD often coexist, but the impact of COPD on prognosis in European AF patients is unknown. METHODS: We evaluated COPD prevalence in patients enrolled in the EURObservational Research Programme Pilot Survey on Atrial Fibrillation Registry Pilot Phase. Clinical factors associated with COPD and adverse outcomes at 1-year follow-up were determined. RESULTS: In the overall cohort, a diagnosis of COPD was recorded in 339 (11.0%) of AF patients. The AF patients with COPD were more burdened with risk factors and comorbidities, including diabetes mellitus (P < .0001) and chronic heart failure (P < .0001). β-Blockers were less likely to be prescribed to patients with COPD (P = .0007). On follow-up, AF patients with COPD had a higher risk of both CV death and all-cause death (both P < .0001), as well as for the composite outcome of any thromboembolic event/bleeding /CV death (P = .0003). Cox regression analysis found that COPD was independently associated with an increase in all-cause death (hazard ratio, 1.55; 95% CI 1.05-2.28; P = .0269). CONCLUSIONS: Chronic obstructive pulmonary disease is highly prevalent in European AF patients, and is associated with higher rates of CV death, all-cause death, and the composite outcome of any thromboembolic event/bleeding/CV death. The presence of COPD in AF patients was independently associated with all-cause death in AF patients.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a common chronic disease, being associated with both high rates of morbidity and mortality. Similarly, atrial fibrillation (AF) is associated with a higher risk of both cardiovascular (CV) events and overall mortality. The AF and COPD often coexist, but the impact of COPD on prognosis in European AFpatients is unknown. METHODS: We evaluated COPD prevalence in patients enrolled in the EURObservational Research Programme Pilot Survey on Atrial Fibrillation Registry Pilot Phase. Clinical factors associated with COPD and adverse outcomes at 1-year follow-up were determined. RESULTS: In the overall cohort, a diagnosis of COPD was recorded in 339 (11.0%) of AFpatients. The AFpatients with COPD were more burdened with risk factors and comorbidities, including diabetes mellitus (P < .0001) and chronic heart failure (P < .0001). β-Blockers were less likely to be prescribed to patients with COPD (P = .0007). On follow-up, AFpatients with COPD had a higher risk of both CV death and all-cause death (both P < .0001), as well as for the composite outcome of any thromboembolic event/bleeding /CV death (P = .0003). Cox regression analysis found that COPD was independently associated with an increase in all-cause death (hazard ratio, 1.55; 95% CI 1.05-2.28; P = .0269). CONCLUSIONS:Chronic obstructive pulmonary disease is highly prevalent in European AFpatients, and is associated with higher rates of CV death, all-cause death, and the composite outcome of any thromboembolic event/bleeding/CV death. The presence of COPD in AFpatients was independently associated with all-cause death in AFpatients.
Authors: Valeria Raparelli; Daniele Pastori; Serena Francesca Pignataro; Anna Rita Vestri; Pasquale Pignatelli; Roberto Cangemi; Marco Proietti; Giovanni Davì; William Robert Hiatt; Gregory Yoke Hong Lip; Gino Roberto Corazza; Francesco Perticone; Francesco Violi; Stefania Basili Journal: Intern Emerg Med Date: 2018-03-26 Impact factor: 3.397
Authors: Moisés Rodríguez-Mañero; Estrella López-Pardo; Alberto Cordero; Alberto Ruano-Ravina; José Novo-Platas; María Pereira-Vázquez; Álvaro Martínez-Gómez; Javier García-Seara; Jose-Luis Martínez-Sande; Carlos Peña-Gil; Pilar Mazón; Jose María García-Acuña; Luis Valdés-Cuadrado; José Ramón González-Juanatey Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-02-12
Authors: Ahmed M Maraey; Muhammad Haisum Maqsood; Mahmoud Khalil; Ahmed Hashim; Ahmed M Elzanaty; Hadeer R Elsharnoby; Eman Elsheikh; Lamiaa Elbatanony; Kenneth Ong; Paul Chacko Journal: J Innov Card Rhythm Manag Date: 2022-08-15
Authors: Bhautesh Dinesh Jani; Barbara I Nicholl; Ross McQueenie; Derek T Connelly; Peter Hanlon; Katie I Gallacher; Duncan Lee; Frances S Mair Journal: Europace Date: 2018-11-01 Impact factor: 5.214